An Exploratory Study of CDK4/6 Inhibitor SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Latest Information Update: 05 Apr 2024
At a glance
- Drugs Dalpiciclib (Primary) ; Famitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 05 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2023).
- 11 Apr 2023 Planned End Date changed from 20 Aug 2022 to 30 Sep 2023.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.